JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO PRESENTED THE PRELIMINARY CLINICAL DATA OF BETINHIBITOR JAB-8263 TO TREAT MYELOFIBROSIS AT THE 2024 66THAMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2024
JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE I/IIa CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN CHINA
JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024
JACOBIO-B: NEXT DAY DISCLOSURE RETURN
JACOBIO-B: NEXT DAY DISCLOSURE RETURN
JACOBIO-B: VOLUNTARY ANNOUNCEMENTGLECIRASIB FOR THE TREATMENT OF PANCREATIC CANCER HASBEEN GRANTED ORPHAN DRUG DESIGNATION IN EUROPE
JACOBIO-B: NEXT DAY DISCLOSURE RETURN
JACOBIO-B: NEXT DAY DISCLOSURE RETURN
JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO PRESENTED THE PRE-CLINICAL DATA OF SHP2 INHIBITORJAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIBAT THE FIFTH RAS INITIATIVE SYMPOSIUM 2024
JACOBIO-B: NEXT DAY DISCLOSURE RETURN
JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2024
JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO TO PRESENT THE CLINICAL DATA OF BET INHIBITORJAB-8263 AT THE 2024 66TH AMERICAN SOCIETY OF HEMATOLOGYANNUAL MEETING
JACOBIO-B: 2024 INTERIM REPORT
JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTOEXCLUSIVE LICENSING-OUT AGREEMENT FOR GLECIRASIB AND JAB-3312 WITH ALLIST
JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO RECEIVED CHINA CDE INVESTIGATIONALNEW DRUG CLEARANCE FOR PAN-KRAS INHIBITOR JAB-23E73
JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM THE U.S. FDA FOR PAN-KRAS INHIBITOR JAB-23E73
JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024
JACOBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
JACOBIO-B: (1) INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024;(2) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND(3) CHANGE IN THE COMPOSITION OF THE REMUNERATIONCOMMITTEE AND THE NOMINATION COMMITTEE
No Data